“This capital raise takes us to the next milestone for our company and demonstrates our maturing operations,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical. “With this investment, we will continue to develop our product pipeline and customer base always with the focus improving the patient experience through our non-invasive drug delivery products.”
Through its solutions, CURE Pharmaceutical works to better the safety and efficacy of new and existing medications. The company’s unique CUREfilm™ technology enables high loads of medicine as well as multiple actives on a single film, while maintaining fast absorption and a pleasant taste.
About CURE Pharmaceutical
CURE Pharmaceutical is a fully integrated drug delivery and development committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry leading full-service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
About Alexander Capital
Founded in 1995, Alexander Capital, L.P. is under new ownership and has become a full-service, boutique investment bank and brokerage firm backed by a team of talented and experienced industry professionals. The core of the firm’s Principals and Executives reflects a broad background in investment banking, sales and trading. Alexander Capital specializes in capital raising, advisory and valuation services for private and public companies of varying sizes, market capitalizations and in multiple sectors. Alexander also services high net worth investors in its Wealth Management division and provides access to products in other financial institutions through its “Open Architecture” investment approach. Alexander Capital, L.P. is a member of FINRA & SIPC and its clearing agent is RBC Correspondent Services.
This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty in predicting the timing or outcome of other product research and development efforts, potential product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company’s judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.